Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis

Cell

Volumn 147, Issue 2, 2011, Pages 306-319

  Grebien, Florian ^a   Hantschel, Oliver ^a   Wojcik, John ^b   Kaupe, Ines ^a   Kovacic, Boris ^c   Wyrzucki, Arkadiusz M ^b,d   Gish, Gerald D ^e   Cerny Reiterer, Sabine ^g   Koide, Akiko ^b   Beug, Hartmut ^c   Pawson, Tony ^e,f   Valent, Peter ^g   Koide, Shohei ^b   Superti Furga, Giulio ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b UNIVERSITY OF CHICAGO   (United States)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^d UNIVERSITY OF GDA SK   (Poland)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABL SH2 BINDING FIBRONECTIN TYPE III MONOBODY; BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PHOSPHOTRANSFERASE; PHOSPHOTYROSINE; PROTEIN KINASE INHIBITOR; PROTEIN SH2; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG SENSITIVITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HEMATOPOIETIC CELL; INTRACELLULAR SIGNALING; LEUKEMIA CELL; LEUKEMOGENESIS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

MUS;

EID: 80054690374     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2011.08.046     Document Type: Article

References (50)

1. P.J. Belshaw, S.N. Ho, G.R. Crabtree, and S.L. Schreiber Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins Proc. Natl. Acad. Sci. USA 93 1996 4604 4607 (Pubitemid 26162809)
2. G.Q. Daley, R.A. Van Etten, and D. Baltimore Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 247 1990 824 830
3. K. De Keersmaecker, M. Versele, J. Cools, G. Superti-Furga, and O. Hantschel Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases Leukemia 22 2008 2208 2216
4. M. Deininger, E. Buchdunger, and B.J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2005 2640 2653 (Pubitemid 40446252)
5. P. Filippakopoulos, M. Kofler, O. Hantschel, G.D. Gish, F. Grebien, E. Salah, P. Neudecker, L.E. Kay, B.E. Turk, and G. Superti-Furga Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation Cell 134 2008 793 803
6. P. Filippakopoulos, S. Müller, and S. Knapp SH2 domains: modulators of nonreceptor tyrosine kinase activity Curr. Opin. Struct. Biol. 19 2009 643 649
7. O. Hantschel, and G. Superti-Furga Regulation of the c-Abl and Bcr-Abl tyrosine kinases Nat. Rev. Mol. Cell Biol. 5 2004 33 44 (Pubitemid 38089839)
8. O. Hantschel, B. Nagar, S. Guettler, J. Kretzschmar, K. Dorey, J. Kuriyan, and G. Superti-Furga A myristoyl/phosphotyrosine switch regulates c-Abl Cell 112 2003 845 857 (Pubitemid 36378886)
9. O. Hantschel, A. Gstoettenbauer, J. Colinge, I. Kaupe, M. Bilban, T.R. Burkard, P. Valent, and G. Superti-Furga The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia Mol. Oncol. 2 2008 272 281
10. A. Hochhaus, S.G. O'Brien, F. Guilhot, B.J. Druker, S. Branford, L. Foroni, J.M. Goldman, M.C. Müller, J.P. Radich, M. Rudoltz IRIS Investigators Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 2009 1054 1061
11. A. Hoelbl, C. Schuster, B. Kovacic, B. Zhu, M. Wickre, M.A. Hoelzl, S. Fajmann, F. Grebien, W. Warsch, and G. Stengl Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia EMBO Mol Med 2 2010 98 110
12. R.L. Ilaria Jr.; and R.A. Van Etten The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells Blood 86 1995 3897 3904
13. E. Jabbour, A. Hochhaus, J. Cortes, P. La Rosée, and H.M. Kantarjian Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history Leukemia 24 2010 6 12
14. R.E. Joseph, L. Min, R. Xu, E.D. Musselman, and A.H. Andreotti A remote substrate docking mechanism for the tec family tyrosine kinases Biochemistry 46 2007 5595 5603 (Pubitemid 46717282)
15. A. Koide, and S. Koide Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain Methods Mol. Biol. 352 2007 95 109
16. B.J. Mayer, H. Hirai, and R. Sakai Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases Curr. Biol. 5 1995 296 305
17. J.R. McWhirter, D.L. Galasso, and J.Y. Wang A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins Mol. Cell. Biol. 13 1993 7587 7595 (Pubitemid 23354283)
18. E.T. Mikkola, and C.G. Gahmberg Hydrophobic interaction between the SH2 domain and the kinase domain is required for the activation of Csk J. Mol. Biol. 399 2010 618 627
19. R.P. Million, and R.A. Van Etten The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase Blood 96 2000 664 670 (Pubitemid 30463389)
20. B. Nagar, O. Hantschel, M.A. Young, K. Scheffzek, D. Veach, W. Bornmann, B. Clarkson, G. Superti-Furga, and J. Kuriyan Structural basis for the autoinhibition of c-Abl tyrosine kinase Cell 112 2003 859 871 (Pubitemid 36378887)
21. B. Nagar, O. Hantschel, M. Seeliger, J.M. Davies, W.I. Weis, G. Superti-Furga, and J. Kuriyan Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase Mol. Cell 21 2006 787 798 (Pubitemid 43376129)
22. M. Nieborowska-Skorska, M.A. Wasik, A. Slupianek, P. Salomoni, T. Kitamura, B. Calabretta, and T. Skorski Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis J. Exp. Med. 189 1999 1229 1242 (Pubitemid 29198261)
23. T. Pawson, G.D. Gish, and P. Nash SH2 domains, interaction modules and cellular wiring Trends Cell Biol. 11 2001 504 511 (Pubitemid 33079144)
24. D. Perrotti, C. Jamieson, J. Goldman, and T. Skorski Chronic myeloid leukemia: mechanisms of blastic transformation J. Clin. Invest. 120 2010 2254 2264
25. A. Quintás-Cardama, H. Kantarjian, and J. Cortes Flying under the radar: the new wave of BCR-ABL inhibitors Nat. Rev. Drug Discov. 6 2007 834 848 (Pubitemid 47500507)
26. R. Ren Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia Nat. Rev. Cancer 5 2005 172 183 (Pubitemid 40314949)
27. S. Roumiantsev, I.E. de Aos, L. Varticovski, R.L. Ilaria, and R.A. Van Etten The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase Blood 97 2001 4 13 (Pubitemid 32061237)
28. I. Sadowski, J.C. Stone, and T. Pawson A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps Mol. Cell. Biol. 6 1986 4396 4408 (Pubitemid 17217381)
29. M. Sattler, M.G. Mohi, Y.B. Pride, L.R. Quinnan, N.A. Malouf, K. Podar, F. Gesbert, H. Iwasaki, S. Li, and R.A. Van Etten Critical role for Gab2 in transformation by BCR/ABL Cancer Cell 1 2002 479 492 (Pubitemid 41039128)
30. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
31. N.P. Shah, and C.L. Sawyers Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias Oncogene 22 2003 7389 7395 (Pubitemid 37487164)
32. N.P. Shah, C. Kasap, C. Weier, M. Balbas, J.M. Nicoll, E. Bleickardt, C. Nicaise, and C.L. Sawyers Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis Cancer Cell 14 2008 485 493
33. D.W. Sherbenou, O. Hantschel, I. Kaupe, S. Willis, T. Bumm, L.P. Turaga, T. Lange, K.-H. Dao, R.D. Press, and B.J. Druker BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib Blood 116 2010 3278 3285
34. N. Vajpai, A. Strauss, G. Fendrich, S.W. Cowan-Jacob, P.W. Manley, S. Grzesiek, and W. Jahnke Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib J. Biol. Chem. 283 2008 18292 18302
35. J. Wojcik, O. Hantschel, F. Grebien, I. Kaupe, K.L. Bennett, J. Barkinge, R.B. Jones, A. Koide, G. Superti-Furga, and S. Koide A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain Nat. Struct. Mol. Biol. 17 2010 519 527
36. S. Wong, and O.N. Witte The BCR-ABL story: bench to bedside and back Annu. Rev. Immunol. 22 2004 247 306 (Pubitemid 38680424)
37. J. Zhang, F.J. Adrián, W. Jahnke, S.W. Cowan-Jacob, A.G. Li, R.E. Iacob, T. Sim, J. Powers, C. Dierks, and F. Sun Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 463 2010 501 506
38. Collaborative Computational Project, Number 4. (1994). The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763.
39. Barilá, D.; and Superti-Furga, G. (1998). An intramolecular SH3-domain interaction regulates c-Abl activity. Nat. Genet. 18, 280-282. (Pubitemid 28117269)
40. Davis, I.W.; Leaver-Fay, A.; Chen, V.B.; Block, J.N.; Kapral, G.J.; Wang, X.; Murray, L.W.; Arendall, W.B.; 3rd, Snoeyink, J.; Richardson, J.S.; and Richardson, D.C. (2007). MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35 (Web Server issue), W375-W383.
41. DeLano, W.L. (2002). The PyMOL Molecular Graphics System. http://pymol.sourceforge.net.
42. Filippakopoulos, P.; Kofler, M.; Hantschel, O.; Gish, G.D.; Grebien, F.; Salah, E.; Neudecker, P.; Kay, L.E.; Turk, B.E.; Superti-Furga, G.; et al. (2008). Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134, 793-803.
43. Garrard, S.M.; Longenecker, K.L.; Lewis, M.E.; Sheffield, P.J.; and Derewenda, Z.S. (2001). Expression, purification, and crystallization of the RGS-like domain from the Rho nucleotide exchange factor, PDZ-RhoGEF, using the surface entropy reduction approach. Protein Expr. Purif. 21, 412-416. (Pubitemid 34179413)
44. Koide, A.; Gilbreth, R.N.; Esaki, K.; Tereshko, V.; and Koide, S. (2007). High-affinity single-domain binding proteins with a binary-code interface. Proc. Natl. Acad. Sci. USA 104, 6632-6637. (Pubitemid 47175552)
45. Kunkel, T.A.; Bebenek, K.; and McClary, J. (1991). Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol. 204, 125-139.
46. Lawrence, M.S.; Phillips, K.J.; and Liu, D.R. (2007). Supercharging proteins can impart unusual resilience. J. Am. Chem. Soc. 129, 10110-10112. (Pubitemid 47312950)
47. Otwinowski, Z.; and Minor, W. (1997). Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326. (Pubitemid 27085611)
48. Painter, J.; and Merritt, E.A. (2006). Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62, 439-450.
49. Potterton, E.; Briggs, P.; Turkenburg, M.; and Dodson, E. (2003). A graphical user interface to the CCP4 program suite. Acta Crystallogr. D Biol. Crystallogr. 59, 1131-1137. (Pubitemid 36872348)
50. Reynolds, C.; Damerell, D.; and Jones, S. (2009). ProtorP: a protein-protein interaction analysis server. Bioinformatics 25, 413-414.